Position in TLPH
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$530,418
+$109,053 QoQ
Shares Held
514,969
-8.3% QoQ
Ownership
0.992%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#9
of 49 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in TLPH Over Time
Shares Held
Position Value (USD)
Derivatives in TLPH
reported options exposure · as of Dec 31, 2025CallValue
$911,544
CallShares
799,600
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Caption Management, LLC holds $32,819,609 across 14 Drug Manufacturers - Specialty & Generic names. TLPH ranks #12 (1.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TEVA |
Teva Pharmaceutical Industries Ltd
|
258,331 | $8,752,254 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
9,333 | $5,056,899 | |
| 3 | NBIX |
Neurocrine Biosciences Inc
|
29,500 | $4,971,930 | |
| 4 | ANIP |
Ani Pharmaceuticals Inc
|
40,000 | $3,311,200 | |
| 5 | PRGO |
PERRIGO Co plc
|
253,459 | $2,633,439 | |
| 6 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
25,000 | $1,598,750 | |
| 7 | XERS |
Xeris Biopharma Holdings, Inc.
|
197,863 | $1,567,074 | |
| 8 | EOLS |
Evolus, Inc.
|
216,316 | $1,501,233 |
All Filings in TLPH
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $530,418 | 514,969 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $421,365 | 561,820 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $911,544 | 799,600 | Call | Sole | 2026-02-17 | |
| 2025-09-30 | $222,500 | 250,000 | Call | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||